Screener
ARS Pharmaceuticals, Inc. SPRY Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 1,968 | 3,237 |
| Interest expense (including related party amounts of $122 and $0, respectively) | (2,441) | — |
| Total other (expense) income, net | (473) | 3,237 |
| Net loss | (60,618) | (33,940) |
| Unrealized losses on available-for-sale securities | (221) | (148) |
| Comprehensive loss | $(60,839) | $(34,088) |
| Net loss per share, basic and diluted | $(0.61) | $(0.35) |
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 99,296,408 | 98,060,636 |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s net income?
- ARS Pharmaceuticals, Inc. (SPRY) reported net income of -$60.62M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s net income changed year-over-year?
- ARS Pharmaceuticals, Inc.'s net income decreased by 78.6% year-over-year, from -$33.94M to -$60.62M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s net income?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s net income has grown at a 70.3% compound annual growth rate (CAGR), from -$34.68M to -$171.3M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about ARS Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude